EMA Accepts MAA for DMB-3115, a Stelara Biosimilar by Dong-A ST

EMA Accepts Marketing Authorization Application for DMB-3115, a Stelara Biosimilar by Dong-A ST &nbsp Confirmation of Therapeutic Equivalence and Safety between DMB-3115 and Stelara in Global Phase III Trial &nbsp SEOUL, South Korea--(BUSINESS WIRE)-- On July 14, Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that the European Medicine Agency (EMA) has accepted the Marketing Autho..